Lynch Syndrome Vaccine Study

About the Study

Lynch Syndrome (LS) increases the risk of colon cancer and other cancers, including cancer of the uterus, ovaries, small bowel, stomach, pancreas, urinary tract, skin, and brain.

This study is being done to assess the safety and effectiveness of a series of vaccines (Tri-Ad5), together with another drug (N-803) that magnifies the body’s response to vaccines, to see if there is an effect on the risk of developing colon and other cancers in LS patients.

For more Information, visit https://bit.ly/ihavelynch

What the Study Involves

If you consent and are eligible to join this trial, you will attend a total of 8 study appointments. During these visits you will receive a series of injections (3-4 injections four times over a one-year period) and undergo yearly colonoscopies as part of routine care. You can also expect physical exams, blood draws, review of your medical history, and completion of questionnaires and a vaccine report card to report any injection side effects.

Study Locations

Arizona

• Tucson, AZ
  University of Arizona Cancer Center - Prevention Research Clinic
  Lead Research, Aaron Scot: 
  Contact: Aaron J. Scott    520-626-6453 ajscott@arizona.edu

Illinois

• Chicago, IL
  Northwestern University
  Lead Researcher: Mohammad A. Abbass
  Contact: Mohammad A. Abbass    312-694-4789    Mohammad.Abbass@nm.org

Kansas

• Kansas City, KS
  University of Kansas Medical Center
  Lead Researcher: Ajay Bansal, MD
  Contact:  913-588-6003    abansal@kumc.edu 

Massachusetts

• Boston, MA
  Dana-Farber Cancer Institute
  Lead Researcher: Ramona M. Lim, MD
  Contact: 617-582-7777    ColonScreening@DFCI.harvard.edu

Michigan

• Ann Arbor, MI
  University of Michigan Comprehensive Cancer Center
  Lead Researcher: Elena Stoffel, MD
  Contact: 734-936-0781    estoffel@med.umich.edu

Texas

• Houston, TX
  University of Texas MD Anderson Cancer Center, Houston, TX
  Lead Researcher: Eduardo Vilar-Sanchez, MD, PhD
  Contact: 713-563-4743    EVilar@mdanderson.org